Theme 07 - PRE-CLINICAL THERAPEUTIC STRATEGIES.

Authors :: Burg, T.
Rossaert, E.
Moisse, M.
Van Damme, P.
Van Den Bosch, L.
Niblock, M.
Sreedharan, J.
Seredenina, T.
Afroz, T.
Chevalier, E.
Ziehm, T.
Audrain, M.
Egesipe, A.
Mottier, L.
Neumann, M.
Havas, D.
Ollier, R.
Piorkowska, K.
Chauhan, M.
Dumayne, C.
Source :: Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration; 2021, Vol. 22, p121-134, 14p
Publication Year :: 2021
Abstract: T-type Ca 2+ enhancer SAK3 activates CaMKII and proteasome activities in Lewy body dementia mice model. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. [Extracted from the article]